3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
46
Paclitaxel
31
pembrolizumab
25
Cyclophosphamide
24
Nivolumab
14
Bevacizumab
14
Topotecan
12
Gemcitabine
12
liposomal doxorubicin
11
Filgrastim
11
Cisplatin
11
fludarabine
10
Peripheral Blood Stem Cell Transplantation
10
olaparib
8
aldesleukin
7
durvalumab
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Docetaxel
6
niraparib
5
epacadostat
5
cemiplimab
5
Ifosfamide
5
Fulvestrant
5
rucaparib
4
poly ICLC
4
pazopanib
4
avelumab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ovarian Neoplasms
×
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
×
Clear all
NCT00574678
2021-08-05
ACT
University of Arkansas
Phase 1/2
Completed
150 enrolled